Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin
about
4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityCombination immunotherapy: a road map.Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Immunotherapy for ovarian cancer.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer modelConcomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanomaDefinitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.Laricitrin ameliorates lung cancer-mediated dendritic cell suppression by inhibiting signal transducer and activator of transcription 3Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.Checkpoint inhibitors in immunotherapy of ovarian cancer.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Immune checkpoint inhibition in ovarian cancer.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy.Predictors of responses to immune checkpoint blockade in advanced melanomaEpigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.Ovarian cancer: how can resistance to chemotherapy be tackled?Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.Tumor Regression and Cure Depends on Sustained Th1 ResponsesSperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
P2860
Q27012963-3529B09E-096E-4209-B1E0-3E08FEBB13A8Q34552128-6C711A1E-BF3B-4049-B39E-3C4880988A85Q35051306-35032C2F-F36E-4958-8051-66CA1B21CCEBQ35107009-C1CE90EB-D7CE-453B-A03A-D2EC3856BA5BQ35164189-05F982A3-69E7-4CA1-834A-ED98A12487DFQ35896426-8B600596-4E97-4DFA-A1E4-078E53DDCAE4Q36413772-28E7A35F-E088-43ED-8482-9A2F5FCD4122Q36936587-6DF2DC5A-03FE-4842-9977-DA52C456BC98Q37100703-EBC01847-B66A-4048-9E3F-2963C834740EQ37616503-271CC164-BED7-4E07-BAF3-D665F7FA89D3Q37709119-4B3948D3-3911-4B5A-A9A9-2BE7D02F9B34Q38247492-857BF492-96F5-425B-B601-958EFDD0A986Q38269568-AFBA73A5-E0FC-4449-9E03-BAF18215FC80Q38440279-92D58406-0F32-4A1D-A2D1-212EA5DC16C8Q38562062-EFDDFC7D-61DC-4899-AEAF-B52334A39A71Q38666253-60335896-35A5-4AA7-8F40-1317B3048A82Q38770458-BDA2C155-46F2-4E22-921B-6274689B9881Q38770814-195FB853-18EE-46D9-9EC8-787A28FBAD41Q38800974-4DBC601F-7A5A-48D0-A3F4-04B58AB1E464Q38806038-507712D9-59B4-44A4-B846-E9226F8E7A54Q39402079-EA92659D-CBCA-419E-B445-D838C4AB3FAEQ40877681-A0E51431-02CC-4C96-A9A9-F6D097B1A5BFQ41701241-C98A15A1-602F-4017-9E2F-A09E06D087B5Q47370837-72733913-4A40-4741-A9DE-4D01D4557534Q47813897-541BA708-646B-4C02-A3E8-9DD816C06543Q49737040-2EC3E09D-DBE3-4622-88E0-B351A5DD8B34Q56876356-345ACA37-B24C-454E-B49B-C3D0D961E5DCQ56889963-CBDCE302-D1D6-426F-8588-88D6DB1A0287
P2860
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@ast
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@en
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@nl
type
label
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@ast
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@en
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@nl
prefLabel
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@ast
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@en
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@nl
P2093
P2860
P3181
P1433
P1476
Combinatorial PD-1 blockade an ...... and synergizes with cisplatin
@en
P2093
Huafeng Wei
Ingegerd Hellstrom
Karl Erik Hellstrom
Kexing Fan
Likun Zhao
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0084927
P407
P50
P577
2013-01-01T00:00:00Z